Wegovy tablets were authorised in the UK on 11 June 2026 for weight management in eligible adults. They offer an oral formulation of semaglutide, with specific fasting, water and waiting instructions that need to fit your daily routine.
The UK tablet is now an authorised medicine
The MHRA authorised Wegovy tablets on 11 June 2026. The adult weight-management criteria are an initial BMI of at least 30, or at least 27 with a weight-related health condition, alongside a reduced-calorie diet and increased activity. Statements that no oral GLP-1 weight-management medicine is licensed in the UK are therefore out of date as of this evidence check.
Authorisation establishes a regulatory decision about a product and its uses. It does not guarantee local stock, NHS funding or suitability for every person who meets a BMI threshold. When comparing a service, ask whether it is offering the licensed Wegovy tablet, the strength on your prescription, and a current supply rather than an expression-of-interest list.
Sources: MHRA: First GLP-1 tablet for weight loss approved in the UK
The daily routine is part of the treatment
Oral semaglutide has precise administration requirements. The UK instructions recommend at least eight hours of fasting beforehand, swallowing the tablet whole with no more than 120 mL of water, and waiting at least 30 minutes before food, drink or other oral medicines. These details support absorption; the tablet is not designed to be added casually to breakfast.
Before choosing an oral formulation, map a normal day and an awkward day: an early shift, a journey, a late meal or a morning with several other medicines. Ask a pharmacist to help plan any competing instructions. A tablet may remove a needle-related concern while introducing a different practical challenge. The right question is whether the prescribed routine is sustainable for you.
What OASIS 4 actually studied
OASIS 4 compared once-daily oral semaglutide 25 mg with placebo in adults with overweight or obesity without diabetes. The estimated mean weight reduction at 64 weeks was 13.6% with semaglutide and 2.2% with placebo. These results describe a study population receiving an organised treatment programme, including dose escalation, rather than a guarantee for someone starting the first tablet.
The trial involved 307 participants. That matters when interpreting how precisely uncommon outcomes can be estimated. It also matters that it was a placebo comparison: it did not randomly assign participants between the tablet and Wegovy injection. Similar-looking average losses in separate studies do not prove equal effects, equal tolerability or equal convenience for an individual.
Sources: New England Journal of Medicine: OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity; European Medicines Agency: Wegovy oral formulation: European regulatory assessment report
The ingredient does not make doses interchangeable
The UK tablet strengths are 1.5, 4, 9 and 25 mg. The usual schedule spends at least one month at each step, progressing towards the maintenance dose. Only one tablet should be taken daily; several smaller tablets should not be assembled into a supposed equivalent dose. If treatment needs to be slowed or changed, the prescriber should provide the plan.
A weekly injection dose cannot be multiplied by seven or divided into daily tablets. The product information includes specific switching provisions and notes variability in oral absorption. If switching is being considered, give the clinician the exact formulation, strength and last dose date. Obtain a written plan that names when the old treatment ends and the new treatment begins.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics
An oral medicine still has systemic effects
Taking a tablet does not remove the need to discuss adverse effects and medical history. Digestive symptoms, dehydration and the other semaglutide precautions remain relevant. Severe persistent abdominal pain needs urgent assessment. Sudden loss of vision needs urgent eye casualty or A&E assessment. A change in formulation should never be treated as a way to make an unexplained serious symptom safe.
Tell the prescriber about all medicines, including those taken on an empty stomach, and about diabetes, kidney or liver problems, previous pancreatitis and pregnancy plans. Semaglutide is not for use during pregnancy or breastfeeding. If a dose is missed, the tablet leaflet advises skipping it and taking the next dose the following day; do not double up.
Sources: NHS: Semaglutide: uses, side effects and precautions; MHRA: MHRA updates semaglutide guidance on very rare NAION; Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet
Judge convenience and price together
Compare the actual number of tablets supplied and the repeat price at the prescribed strength. Do not assume that 'monthly' means the same duration for every service. Ask whether assessment, delivery and ongoing clinical contact are included, and whether a promotional price applies only to the first order. A convenient package should still leave you able to get help when the routine or tolerability becomes difficult.
NHS use requires its own appraisal and commissioning decisions. In September 2026, the Scottish Medicines Consortium's non-submission advice did not recommend Wegovy tablets for NHS Scotland; this is a funding position, not a reversal of UK authorisation. Check your own nation's current pathway. Published access information about the injection should not automatically be applied to the tablet.
Sources: Scottish Medicines Consortium: Semaglutide tablets: NHS Scotland non-submission advice, September 2026; General Pharmaceutical Council and UK health organisations: How to keep safe when getting medicines or treatment online; MHRA: First GLP-1 tablet for weight loss approved in the UK
Compare prices for your prescribed dose
The tablet schedule starts at 1.5 mg daily and progresses through 4 mg and 9 mg towards 25 mg, with at least one month at each step. Take only the prescribed tablet strength; do not combine tablets to create a higher dose.
These are first-order price observations, not prescribing recommendations. Repeat costs and additional fees may differ.
Questions, answered.
Can I take the tablet with my morning coffee?
The instructions require water only when taking the tablet, followed by at least 30 minutes before other drinks or food. Plan coffee after that interval.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet
Is Wegovy pill the same as Rybelsus?
Both contain semaglutide, but they are different branded products with their own strengths, indications and instructions. Do not substitute one for the other without a prescription plan.
Sources: NHS: Semaglutide: uses, side effects and precautions; MHRA: First GLP-1 tablet for weight loss approved in the UK
Does oral treatment avoid all the injection's side effects?
No. The active medicine still acts throughout the body. A prescriber should discuss risks for the oral formulation and your medical history.
Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet
Sources & further reading
Original sources for this guide. Source checks are not independent clinical review.
- First GLP-1 tablet for weight loss approved in the UKMHRA · Accessed 19 November 2026
- Wegovy tablets: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- Wegovy tablets: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
- OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or ObesityNew England Journal of Medicine · Accessed 19 November 2026
- Wegovy oral formulation: European regulatory assessment reportEuropean Medicines Agency · Accessed 19 November 2026
- Semaglutide: uses, side effects and precautionsNHS · Accessed 19 November 2026
- MHRA updates semaglutide guidance on very rare NAIONMHRA · Accessed 19 November 2026
- Semaglutide tablets: NHS Scotland non-submission advice, September 2026Scottish Medicines Consortium · Accessed 19 November 2026
- How to keep safe when getting medicines or treatment onlineGeneral Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
